Author

Robert E. Quadro

Observed names: R Quadro, R. Quadro

Institutions: Spectrum Health, University of California San Diego, Corewell Health Blodgett Hospital

Observed institutions: Spectrum Health, University of California San Diego, Corewell Health Blodgett Hospital, University of California Davis Medical Center, University of California, Davis

OpenAlex ID: A5073674497

Epirubicin in non-oat cell lung cancer--response rates and the importance of immunopathology: a Northern California Oncology Group Study.

1986 · F J Meyers, R D Cardiff, et al. · PubMed · 13

5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: Phase II study results

2006 · T. Reid, C. P. Spears, et al. · Journal of Clinical Oncology · 2

A Simon 2 stage study of 5,10 methylenetetrahydrofolic acid (CO) with 5-fluorouracil (FU) as first line treatment in metastatic colorectal cancer (mCRC)

2005 · T. R. Reid, C. P. Spears, et al. · Journal of Clinical Oncology · 2

Measuring functioning hepatocytes using Tc-99m galactosylneoglycoalbumin (Tc-NGA)

1984 · Robert C. Stadalnik, David R. Vera, et al. · Journal of Nuclear Medicine

Tc-99m Galactosyl-neoglycoalbumin (tc-nga)

1983 · Robert C. Stadalnik, David R. Vera, et al. · Clinical Nuclear Medicine

Tc-99m Galactosyl-neoglycoalbumin (tc-nga): a Predictor of Functioning Hepatocyte Mass.

1983 · Robert C. Stadalnik, David R. Vera, et al. · Clinical Nuclear Medicine

Works count: 6

Citation count: 17

H-index: 2

I10-index: 1